Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors

Tricking the balance: NK cells in anti-cancer immunity

(2017) Jens Pahl et al.   IMMUNOBIOLOGY

Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis

(2017) Rosa Molfetta et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAF V600E Melanoma Lines with Vemurafenib

(2017) Alexandra Frazao et al.   Cancer Immunology Research

B-Raf Inhibition in the Clinic: Present and Future

(2016) Warren Fiskus et al.   Annual Review of Medicine

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency

(2016) F. Zhao et al.   CANCER RESEARCH

The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond

(2016) Ziqiang Zhu et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma

(2016) Zachary A. Cooper et al.   OncoImmunology

HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors

(2015) Rosa Sottile et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma

(2015) S. D. Bradley et al.   Cancer Immunology Research

Melanoma

(2015) Dirk Schadendorf et al.   Nature Reviews Disease Primers

Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma

(2014) L. Ferrari de Andrade et al.   CANCER RESEARCH

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Intracellular Retention of the NKG2D Ligand MHC Class I Chain-Related Gene A in Human Melanomas Confers Immune Privilege and Prevents NK Cell-Mediated Cytotoxicity

(2014) M. B. Fuertes et al.   JOURNAL OF IMMUNOLOGY

Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients

(2014) Talib Hassan Ali et al.   Nature Communications

Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

(2014) Z. A. Cooper et al.   Cancer Immunology Research

The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells

(2014) Cristina Cerboni et al.   Frontiers in Immunology

The anticancer effects of HDAC inhibitors require the immune system

(2014) Alison C West et al.   OncoImmunology

Regulation of Ligands for the NKG2D Activating Receptor

(2013) David H. Raulet et al.   Annual Review of Immunology

Mature Cytotoxic CD56bright/CD16+ Natural Killer Cells Can Infiltrate Lymph Nodes Adjacent to Metastatic Melanoma

(2013) M. Messaoudene et al.   CANCER RESEARCH

Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15R  and NKG2D Triggering

(2013) A. I. Romero et al.   CANCER RESEARCH

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

(2013) Deborah A. Knight et al.   JOURNAL OF CLINICAL INVESTIGATION

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

(2013) Antoni Ribas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in BRAFV600E Melanoma Cells

(2013) D. Beck et al.   Science Signaling

Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy

(2013) D. B. Johnson et al.   Cancer Immunology Research

RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry

(2012) Heiyoun Jung et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ras Activation Induces Expression of Raet1 Family NK Receptor Ligands

(2012) X. V. Liu et al.   JOURNAL OF IMMUNOLOGY

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Vemurafenib

(2011) Keith. T Flaherty et al.   NATURE REVIEWS DRUG DISCOVERY

HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank

(2009) Rosa Mendez et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines

(2009) Javier G. Casado et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Current systemic therapy for metastatic melanoma

(2009) Sanjiv S Agarwala   Expert Review of Anticancer Therapy

NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo

(2009) Tadepally Lakshmikanth et al.   JOURNAL OF CLINICAL INVESTIGATION

Proteasome Regulation of ULBP1 Transcription

(2009) James E. Butler et al.   JOURNAL OF IMMUNOLOGY

Interferon-γ down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells

(2008) Nicole Schwinn et al.   INTERNATIONAL JOURNAL OF CANCER